TY  - JOUR
AU  - Merz, Maximilian
AU  - Salwender, Hans
AU  - Haenel, Mathias
AU  - Mai, Elias K
AU  - Bertsch, Uta
AU  - Kunz, Christina
AU  - Hielscher, Thomas
AU  - Blau, Igor W
AU  - Scheid, Christof
AU  - Hose, Dirk
AU  - Seckinger, Anja
AU  - Jauch, Anna
AU  - Hillengass, Jens
AU  - Raab, Marc-Steffen
AU  - Schurich, Baerbel
AU  - Munder, Markus
AU  - Schmidt-Wolf, Ingo G H
AU  - Gerecke, Christian
AU  - Lindemann, Hans-Walter
AU  - Zeis, Matthias
AU  - Weisel, Katja
AU  - Duerig, Jan
AU  - Goldschmidt, Hartmut
TI  - Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial.
JO  - Haematologica
VL  - 100
IS  - 7
SN  - 1592-8721
CY  - Pavia
PB  - Ferrata Storti Foundation
M1  - DKFZ-2017-03148
SP  - 964 - 969
PY  - 2015
AB  - We investigated the impact of subcutaneous versus intravenous bortezomib in the MM5 trial of the German-Speaking Myeloma Multicenter Group which compared bortezomib, doxorubicin, and dexamethasone with bortezomib, cyclophosphamide, and dexamethasone induction therapy in newly diagnosed multiple myeloma. Based on data from relapsed myeloma, the route of administration for bortezomib was changed from intravenous to subcutaneous after 314 of 604 patients had been enrolled. We analyzed 598 patients who received at least one dose of trial medication. Adverse events were reported more frequently in patients treated with intravenous bortezomib (intravenous=65
KW  - Antineoplastic Agents (NLM Chemicals)
KW  - Bortezomib (NLM Chemicals)
KW  - Dexamethasone (NLM Chemicals)
KW  - Doxorubicin (NLM Chemicals)
KW  - Cyclophosphamide (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:25840597
C2  - pmc:PMC4486231
DO  - DOI:10.3324/haematol.2015.124347
UR  - https://inrepo02.dkfz.de/record/127122
ER  -